Argent Biopharma Limited has released a press release.
Trial on the Effect of CannEpil on Driver Competency
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Argent Biopharma
- Canaccord to Lead LSE Listing and $4.75m Placement Closed
- MXC 100 Patient Milestone in Aus, Onboards Tetra Health
- MGC Signs Agreement for Construction of GMP Pharma Facility
- Additional Information on Ground-breaking Research
- MGC Research- Effectiveness of Cannabinoids on Brain Cancers
Later from Argent Biopharma
- Approval Granted for Large-Scale Research Project with IHPS
- Appendix 4E and Audited 2019 Financial Report
- Placement Settlement Complete, Info on the Priority Offer
- Epilepsy Clinical Study Comparing CannEpil to 100% CBD
- 200 Prescription Milestone Passed in Australia & UK
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma